On Wednesday, Baird made adjustments to its financial outlook for ICON plc (NASDAQ:ICLR) stock, a global provider of outsourced development services to the pharmaceutical, biotechnology, and medical ...
The DCF model suggests that ICON is undervalued by 98.23%. Between 2018 and 2024, the company's revenues increased by 219.04% and by 145.30%, respectively. This year, ICLR will implement a program to ...
ICON may be relatively undervalued, trading at a ~10% discount to IQVIA and offering an attractive ~7% free cash flow yield that markets seem to be responding to now. The CRO sector faces near-term ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Icon ( (ICLR)) has issued an update. ICON ...
ICON also reaffirmed its guidance for the full year 2024, with expected revenue ranging from $8,260 million to $8,300 million and adjusted EPS between $13.90 and $14.10. Additionally, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback